Tuesday, March 11, 2014
Talk about timing - Oxigene reports positive topline results from randomized phase 2 study of Zybrestat - stock is up over 18%!
I wrote an article yesterday about the most overpriced and underpriced biotechs. Oxigene (OXGN) was my pick for most undervalued due to it's upcoming phase 2 results of it's lead compound, Zybrestat, to treat Ovarian cancer. Results are out and they are communicating positive topline results; stock is up over 18% in the last few minutes of trading.